# Peking Jabrehoo Med Tech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peking-jabrehoo-med-tech-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.jabrehoo.com
- Total disclosed funding: $14M
- Latest round: Series B (Aug 10, 2020)
- Investors on record: 6

## About

Peking Jabrehoo Med Tech Co., Ltd is a medical technology company focused on genetic testing and reproductive health services, providing advanced solutions to enhance pregnancy outcomes through comprehensive genetic assessments.Peking Jabrehoo Med Tech Co., Ltd specializes in genetic testing and reproductive health solutions. Founded in 2011 in Beijing, China, the company has evolved with a focus on providing a range of pre-implantation genetic testing services. The founder, Jia Fei, has a background in the medical technology sector, contributing to the company's innovative approaches. The company raised RMB 100 million in Series B funding on August 10, 2020, primarily from Apricot Capital, totaling RMB 100 million raised since inception.Peking Jabrehoo Med Tech Co., Ltd offers advanced genetic testing services, including pre-implantation genetic testing for aneuploidy (PGT-A), single-gene disorders (PGT-M), and chromosomal structural rearrangements (PGT-SR). Their solutions are designed for individuals and couples undergoing assisted reproductive technologies like in vitro fertilization (IVF), helping to identify genetic abnormalities in embryos. Additionally, the company provides prenatal screening, non-invasive prenatal testing (NIPT), and fertility assessments, catering to fertility clinics and healthcare providers across international markets, particularly in Asia and Europe.The company generates revenue through B2B transactions with fertility clinics and healthcare institutions, charging clients on a fee-per-test basis for services like PGT-A, PGT-M, and PGT-SR. This pricing strategy is tailored to meet a diverse clientele's needs, ensuring access to quality genetic testing services. Revenue is further supported by partnerships for research and development with medical institutions, fostering long-term relationships and maintaining a prominent market presence.In the wake of the RMB 100 million raised in Series B funding in August 2020, Peking Jabrehoo Med Tech Co., Ltd plans to expand its product offerings, including the launch of new genetic testing services tailored for emerging reproductive health needs. The company is strategically targeting expansion into new markets across Asia and Europe by the end of 2023, leveraging its recent funding to support these initiatives and enhance its operational capabilities.

## Funding rounds

- Series B, Aug 10, 2020, $14M — Apricot Capital
- Series C, Apr 25, 2018 — GTJA Investment Group
- Series A, Aug 17, 2015 — Lotus Lake Capital, LYFE Capital, Ch-Gemstone Capital, Tengye Ventures

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- LYFE Capital — Series A
- Ch-Gemstone Capital — Series A
- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Series A
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series C
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series B